BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in ChinaBusiness Wire • 12/15/21
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of ChinaBusiness Wire • 12/14/21
Here are the 10 U.S.-listed Chinese stocks with the greatest American ownership — and Alibaba's not one of themCNBC • 12/14/21
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual MeetingBusiness Wire • 12/12/21
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell MalignanciesBusiness Wire • 12/11/21
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021Business Wire • 12/10/21
BeiGene - EUSA Pharma's Siltuximab Approved In China For Multicentric Castleman DiseaseBenzinga • 12/03/21
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman DiseaseBusiness Wire • 12/03/21
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for PamiparibBusiness Wire • 12/03/21
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021Business Wire • 12/02/21
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in ChinaBusiness Wire • 11/30/21
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström's MacroglobulinemiaBusiness Wire • 11/23/21
BeiGene Launches Proposed Initial Public Offering on the STAR Market in ChinaBusiness Wire • 11/23/21
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D CenterBusiness Wire • 11/23/21
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339Business Wire • 11/22/21
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 11/15/21
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual MeetingBusiness Wire • 11/04/21
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 10/20/21
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell LymphomaBusiness Wire • 10/10/21
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in AustraliaBusiness Wire • 10/10/21
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström's MacroglobulinemiaBusiness Wire • 10/07/21
